当前位置: 首页 >> 检索结果
2682. Corin and Left Atrial Cardiomyopathy, Hypertension, Arrhythmia, and Fibrosis.
作者: John Dominy.;Christopher Koch.;Lindsey Lamarche.;Daniel Denning.;Allan Gurtan.;Maleeha Z Khan.;Asif Rasheed.;Muhammad R Mian.;Muhammad Jahanzaib.;Shareef Khalid.;Danish Saleheen.
来源: N Engl J Med. 2024年390卷16期1537-1538页 2696. Nutritional Support for Moderate-to-Late-Preterm Infants - A Randomized Trial.
作者: Tanith Alexander.;Sharin Asadi.;Michael Meyer.;Jane E Harding.;Yannan Jiang.;Jane M Alsweiler.;Mariana Muelbert.;Frank H Bloomfield.; .
来源: N Engl J Med. 2024年390卷16期1493-1504页
Most moderate-to-late-preterm infants need nutritional support until they are feeding exclusively on their mother's breast milk. Evidence to guide nutrition strategies for these infants is lacking.
2697. Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
作者: Yongxian Hu.;Mingming Zhang.;Tingting Yang.;Zhuomao Mo.;Guoqing Wei.;Ruirui Jing.;Houli Zhao.;Rongrong Chen.;Cheng Zu.;Tianning Gu.;Pingnan Xiao.;Ruimin Hong.;Jingjing Feng.;Shan Fu.;Delin Kong.;Huijun Xu.;Jiazhen Cui.;Simao Huang.;Bin Liang.;Xiaolin Yuan.;Qu Cui.;Hongshan Guo.;Yunxian Yu.;Youqin Feng.;Chunxiang Jin.;Jiangtao Ren.;Alex H Chang.;Dongrui Wang.;He Huang.
来源: N Engl J Med. 2024年390卷16期1467-1480页
Patients with relapsed or refractory hematologic cancers have a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapy as a bridge to allogeneic hematopoietic stem-cell transplantation (HSCT) has the potential for long-term tumor elimination. However, pre-HSCT myeloablation and graft-versus-host disease (GVHD) prophylaxis agents have toxic effects and could eradicate residual CAR T cells and compromise antitumor effects. Whether the integration of CAR T-cell therapy and allogeneic HSCT can preserve CAR T-cell function and improve tumor control is unclear.
|